Contact Pfizer Media Relations
This information is intended for media professionals.
This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may ONLY respond to calls and emails from professional journalists.
If you are not a journalist, please visit the Contact Page and consult the appropriate Pfizer contact.
Phone: (212) 573-1226
For specific media inquiries:
Europe/Africa/Middle East, email wwce@pfizer.com
You can also visit our Pfizer Worldwide Web Sites.
| Contact |
Responsibility |
Key Products/Issues (not inclusive) |
|---|---|---|
| Ray Kerins W: 212-733-9203 C: 917-324-0080 Ray.Kerins@pfizer.com |
Global Head of Media Relations | |
| Vanessa Aristide W: 212-733-3784 C: 917-697-0481 Vanessa.Aristide@pfizer.com |
Cardiovascular; Metabolic and Oncology | Lipitor, Exubera, Sutent |
| Jack Cox W: 212-733-5017 C: 917-514-2858 Jack.Cox@pfizer.com |
Central Nervous System; Pain | Aricept, Geodon, Lyrica |
| Sally Beatty W: 212-733-6566 C: 347-330-7867 Sally.Beatty@pfizer.com |
Urology; Respiratory; Anti-infective | Chantix, Viagra, Selzentry/Celsentri |
| Chris Loder W: 212-733-7897 C: 347-453-8199 Christopher.Loder@pfizer.com |
Litigation; Policy; Manufacturing | Trovan (case in Nigeria), Cox-2 litigation, Counterfeiting |
| Shreya Jani W: 212-733-4889 C: 917-743-4349 Shreya.Jani@pfizer.com |
Finance; Earnings/SEC filings; Corporate Governance; Business Development; HIV/AIDS | Earnings releases, Acquisitions, Business Deals |
| Liz Power W: 860-732-4987 C: 860-501-3849 Elizabeth.Power@pfizer.com |
PGRD, BBC, Pipeline | |
| Imraan Munshi W: 212-733-6197 C: 917-208-3021 Imraan.Munshi@pfizer.com |
Asia/Japan, Canada | |
| Oliver Stohlmann W: 43 1 52115 337 C: 43 664 3350485 Oliver.Stohlmann@pfizer.com |
Europe | EU/local corporate, Lipitor, Champix, Oncology, COX-2, all brands |
| Lisa O'Neill W: 44 1737 331536 C: 44 7967 756924 Lisa.O'Neill@pfizer.com |
Europe | R&D/science, Viagra, Lyrica, Aricept, CNS, Ophthalmology, Counterfeit Medicines |
| Bernard Peyrical C: 33 670 169505 Bernard.Peyrical@pfizer.com |
Europe | European policy, HIV and Infectiology, Urology, Oncology |
| Gulden Mesara W: 902 1231 07521 C: 905 3246 79904 Gulden.Mesara@pfizer.com |
Africa, Middle East | |
| Francisco Gebauer W: 212-733-5191 C: 917-912-7688 Francisco.Gebauer@pfizer.com |
Latin America | |
| Rick Chambers W: 269-833-6387 C:269-760-0770 Richard.T.Chambers@pfizer.com |
U.S. West | Marketing/Business Practices |
| Huw Gilbert W: 212-733-8926 C: 347-229-4560 Huw.Gilbert@pfizer.com |
U.S. East | Marketing/Business Practices |
| Rick Goulart W: 212-733-7457 C: 860-501-3391 Rick.Goulart@pfizer.com |
Animal Health |
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Stock Symbol: PFE Stock Exchange: NYSE
Stock Quote at: Dec 4 2008 4:00PM
| Last 16.27 | Change -0.35 |
| %Change | -2.11 | Vol. | 47,497,109 |
| Day High | 16.85 | 52 Wk. High | 24.50 |
| Day Low | 16.14 | 52 Wk. Low | 14.26 |
| Open | 16.36 | Mkt. Cap(Bil) | 109.71 |
| Prev. Close | 16.62 |
Learn more about our progress in building a foundation for solid, sustainable growth and
our promise to continue
as a leader in meeting
one of the world's most basic needs: better health care for more people.

